BMO Capital lowered the firm’s price target on Neurocrine to $114 from $128 and keeps a Market Perform rating on the shares as part of a broader research note previewing Q3 results in BioPharma. Ingrezza growth has continued to be strong and consistent in recent memory, but scripts appear to suggest further slowing in uptake heading into the quarter, the analyst tells investors in a research note. BMO adds that it sees Q3 Ingrezza revenue reaching $585M, which is below consensus of $591M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences Names Dr. Gano as President and CEO
- Nike upgraded, PayPal downgraded: Wall Street’s top analyst calls
- Neurocrine resumed with an Outperform at Raymond James
- Neurocrine announces interim results from ongoing KINECT-HD2 study
- Voyager advances Neurocrine collaboration, selects third gene therapy candidate